A Fortune 500 multinational packaged foods company sought to drive growth in a legacy fiber snack bar brand by launching new product line extensions with a re-formulated fiber ingredient.
Development of a research plan to examine 4 test product iterations of an inulin fiber bar amongst 400 participants across the US. The 100% virtual RCT collected data on clinical efficacy, GI tolerance, and consumer perceptions. 400 participants were recruited across 48 states in 24 days.
• The study achieved 85% questionnaire compliance and an impressive 92% retention rate.
• Data dashboards showed live results during the study.
• New insights on GI response and product likeability informed product development and marketing claims.
A Fortune 500 multinational packaged foods company sought to drive growth in a legacy fiber snack bar brand by launching new product line extensions with a re-formulated fiber ingredient.
Development of a research plan to examine 4 test product iterations of an inulin fiber bar amongst 400 participants across the US. The 100% virtual RCT collected data on clinical efficacy, GI tolerance, and consumer perceptions. 400 participants were recruited across 48 states in 24 days.
• The study achieved 85% questionnaire compliance and an impressive 92% retention rate.
• Data dashboards showed live results during the study.
• New insights on GI response and product likeability informed product development and marketing claims.
A Fortune 500 multinational packaged foods company sought to drive growth in a legacy fiber snack bar brand by launching new product line extensions with a re-formulated fiber ingredient.
Development of a research plan to examine 4 test product iterations of an inulin fiber bar amongst 400 participants across the US. The 100% virtual RCT collected data on clinical efficacy, GI tolerance, and consumer perceptions. 400 participants were recruited across 48 states in 24 days.
• The study achieved 85% questionnaire compliance and an impressive 92% retention rate.
• Data dashboards showed live results during the study.
• New insights on GI response and product likeability informed product development and marketing claims.
A Fortune 500 multinational packaged foods company sought to drive growth in a legacy fiber snack bar brand by launching new product line extensions with a re-formulated fiber ingredient.
Development of a research plan to examine 4 test product iterations of an inulin fiber bar amongst 400 participants across the US. The 100% virtual RCT collected data on clinical efficacy, GI tolerance, and consumer perceptions. 400 participants were recruited across 48 states in 24 days.
• The study achieved 85% questionnaire compliance and an impressive 92% retention rate.
• Data dashboards showed live results during the study.
• New insights on GI response and product likeability informed product development and marketing claims.
A Fortune 500 multinational packaged foods company sought to drive growth in a legacy fiber snack bar brand by launching new product line extensions with a re-formulated fiber ingredient.
Development of a research plan to examine 4 test product iterations of an inulin fiber bar amongst 400 participants across the US. The 100% virtual RCT collected data on clinical efficacy, GI tolerance, and consumer perceptions. 400 participants were recruited across 48 states in 24 days.
• The study achieved 85% questionnaire compliance and an impressive 92% retention rate.
• Data dashboards showed live results during the study.
• New insights on GI response and product likeability informed product development and marketing claims.
A Fortune 500 multinational packaged foods company sought to drive growth in a legacy fiber snack bar brand by launching new product line extensions with a re-formulated fiber ingredient.
A Fortune 500 multinational packaged foods company sought to drive growth in a legacy fiber snack bar brand by launching new product line extensions with a re-formulated fiber ingredient.
Development of a research plan to examine 4 test product iterations of an inulin fiber bar amongst 400 participants across the US. The 100% virtual RCT collected data on clinical efficacy, GI tolerance, and consumer perceptions. 400 participants were recruited across 48 states in 24 days.
• The study achieved 85% questionnaire compliance and an impressive 92% retention rate.
• Data dashboards showed live results during the study.
• New insights on GI response and product likeability informed product development and marketing claims.
A Fortune 500 multinational packaged foods company sought to drive growth in a legacy fiber snack bar brand by launching new product line extensions with a re-formulated fiber ingredient.
A Fortune 500 multinational packaged foods company sought to drive growth in a legacy fiber snack bar brand by launching new product line extensions with a re-formulated fiber ingredient.
Development of a research plan to examine 4 test product iterations of an inulin fiber bar amongst 400 participants across the US. The 100% virtual RCT collected data on clinical efficacy, GI tolerance, and consumer perceptions. 400 participants were recruited across 48 states in 24 days.
• The study achieved 85% questionnaire compliance and an impressive 92% retention rate.
• Data dashboards showed live results during the study.
• New insights on GI response and product likeability informed product development and marketing claims.
ObvioHealth successfully conducted a clinical trial for RedHill Biopharma to test the safety and efficacy of an oral medication for the treatment of COVID-19 symptoms. We designed this decentralized study to be conducted where the majority of patients recover from illness—in their homes. When the trial was launched in 2021, its unique combination of home health visits, electronic patient-reported outcomes (ePRO), and remote monitoring devices was pioneering—COVID-19 studies were typically conducted inside hospitals.
ObvioHealth and Renovia conducted a groundbreaking study on the efficacy of an at-home medical device for the treatment of stress and mixed urinary incontinence. Read more below to understand how we delivered a successful, fully virtual clinical trial in the midst of the pandemic.